Antonelli Alessandro, Rotondi Mario, Fallahi Poupak, Romagnani Paola, Ferrari Silvia Martina, Paolicchi Aldo, Ferrannini Ele, Serio Mario
Metabolism Unit, Department of Medicine and CNR Institute of Clinical Physiology, University of Pisa School of Medicine, Pisa, Italy.
Eur J Endocrinol. 2005 Feb;152(2):171-7. doi: 10.1530/eje.1.01847.
To measure serum levels of CXCL10 and CCL2 prototype chemokines of the two major subclass (CXC and CC) in patients with newly diagnosed chronic autoimmune thyroiditis (AT), and relate the findings to the clinical phenotype.
Serum CXCL10 and CCL2 were assayed in 70 consecutive patients with newly diagnosed chronic AT, in sex- and age-matched healthy volunteers (n = 37) and in 20 patients with non-toxic multinodular goiter, extracted from a random sample of the general population from the same geographic area.
CXCL10 serum levels were significantly higher in patients with thyroiditis than in controls or multinodular goiter patients, while comparable CCL2 levels were found between groups. CXCL10 levels were significantly increased in hypothyroid patients and in those with an hypoechoic pattern (P = 0.0004 and P = 0.0001, respectively) while serum CCL2 levels were significantly increased in patients older than 50 years and in those with hypothyroidism (P = 0.0001 and P = 0.03, respectively). No correlation between CXCL10 and CCL2 serum levels could be demonstrated. CXCL10 and CCL2 were studied separately in relation to clinical features of AT patients. Two separate multiple linear regression models for CXCL10 and CCL2 were performed, including age, thyroid volume, thyroid stimulating hormone (TSH), FT4, anti-thyroid peroxidase (AbTPO), hypoechoic pattern, and the presence of hypervascularity, demonstrating that ln of serum CXCL10 levels was associated with TSH independently of other possible confounders levels [regression coefficient (R.C.) 0.143 confidence interval (C.I.) (0.042-0.245); P = 0.0059], while serum CCL2 were significantly associated only with age [R.C. 5.412 C.I. (3.838-6.986); P < 0.0001].
Our results, obtained in a large cohort of newly diagnosed AT patients demonstrate increased CXCL10 especially in hypothyroid patients with a more aggressive disorder, and normal CCL2 serum levels in AT.
检测新诊断的慢性自身免疫性甲状腺炎（AT）患者血清中两种主要亚类（CXC和CC）的趋化因子CXCL10和CCL2水平，并将结果与临床表型相关联。
对70例连续新诊断的慢性AT患者、性别和年龄匹配的健康志愿者（n = 37）以及从同一地理区域的普通人群随机样本中选取的20例非毒性多结节性甲状腺肿患者检测血清CXCL10和CCL2。
甲状腺炎患者的血清CXCL10水平显著高于对照组或多结节性甲状腺肿患者，而各组间CCL2水平相当。甲状腺功能减退患者和低回声型患者的CXCL10水平显著升高（分别为P = 0.0004和P = 0.0001），而50岁以上患者和甲状腺功能减退患者的血清CCL2水平显著升高（分别为P = 0.0001和P = 0.03）。未发现CXCL10和CCL2血清水平之间存在相关性。分别针对AT患者的临床特征研究了CXCL10和CCL2。针对CXCL10和CCL2进行了两个独立的多元线性回归模型，包括年龄、甲状腺体积、促甲状腺激素（TSH）、游离甲状腺素（FT4）、抗甲状腺过氧化物酶（AbTPO）、低回声型以及血管增多情况，结果表明血清CXCL10水平的自然对数与TSH独立相关，不受其他可能混杂因素水平的影响[回归系数（R.C.）0.143，置信区间（C.I.）（0.042 - 0.245）；P = 0.0059]，而血清CCL2仅与年龄显著相关[R.C. 5.412，C.I.（3.838 - 6.986）；P < 0.0001]。
我们在一大群新诊断的AT患者中获得的结果表明，CXCL10升高，尤其是在病情更严重的甲状腺功能减退患者中，而AT患者的CCL2血清水平正常。
